Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
ERJ Open Research|December 11, 2023
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional studyCristina Candal-Pedreira, Alberto Ruano-Ravina, Virginia Calvo de Juan, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2023
Immunogenicity of COVID-19 vaccines in lung cancer patientsMariano Provencio, Anna Estival, Fernando Franco, et al.
Translational Lung Cancer Research|December 3, 2021
Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide studyAlberto Ruano-Ravina, Mariano Provencio, Virginia Calvo de Juan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2026
Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy from a first-in-human study of volrustomig, a novel PD-1/CTLA-4 bispecific antibodyBen Tran, Mark Voskoboynik, Sang-We Kim, et al.
The Lancet Regional Health. Europe|February 2, 2026
Incidence of second primary cancers in lung cancer survivors by oncological treatment: a nationwide prospective cohort study in SpainMariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutationsRafael Rosell, Miguel Angel Molina, Carlota Costa, et al.
BMC Cancer|July 5, 2022
Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristicsMariano Provencio, Manuel Cobo, Delvys Rodriguez-Abreu, et al.
Cancer Epidemiology|May 26, 2020
Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimationMiguel Barquín, Virginia Calvo, Francisco García-García, et al.
JAMA Oncology|July 17, 2015
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC TrialNiki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt, et al.
Pageof 11